Marker Therapeutics Announces $16.1 Million Private Placement

Core Viewpoint - Marker Therapeutics, Inc. has announced a private placement resulting in gross proceeds of $16.1 million to support the clinical advancement of its Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or are ineligible for it [1][2]. Financing Details - The financing will support the collection of additional clinical data for Marker’s lead clinical asset in lymphoma, MT-601 [3]. - The company is selling 5,031,250 shares of common stock at a purchase price of$3.20 per share, along with accompanying warrants [4]. - The pre-funded warrants will be exercisable at a price of $0.001 per share, while the accompanying warrants will have an exercise price of$4.03 per share [5]. Clinical Study Information - MT-601 is a multi-antigen recognizing (MAR) T cell product targeting six different tumor antigens upregulated in lymphoma cells [8]. - The APOLLO trial is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma [9]. - The trial aims to enroll approximately 30 participants across nine clinical sites in the United States during the dose escalation phase [9]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, focusing on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [12]. - The company’s unique T cell platform is supported by non-dilutive funding from U.S. state and federal agencies [12].